XML 53 R43.htm IDEA: XBRL DOCUMENT v3.20.2
Fair Value of Financial Instruments (Tables)
9 Months Ended
Sep. 30, 2020
Fair Value Disclosures [Abstract]  
Fair Value Hierarchy Tables Present Information about Assets and Liabilities Measured at Fair Value on a Recurring Basis
The following fair value hierarchy table presents information about our assets and liabilities that are measured at fair value on a recurring basis as of September 30, 2020:
(Dollars in thousands)Level 1Level 2Level 3Balance at September 30, 2020
Assets:
Available-for-sale securities:
U.S. Treasury securities$4,547,294 $— $— $4,547,294 
U.S. agency debentures— 152,526 — 152,526 
Foreign government debt securities23,449 — — 23,449 
Residential mortgage-backed securities:
Agency-issued mortgage-backed securities— 9,770,313 — 9,770,313 
Agency-issued collateralized mortgage obligationsfixed rate
— 7,315,973 — 7,315,973 
Agency-issued commercial mortgage-backed securities— 4,094,769 — 4,094,769 
Total available-for-sale securities4,570,743 21,333,581 — 25,904,324 
Non-marketable and other equity securities (fair value accounting):
Non-marketable securities:
Venture capital and private equity fund investments measured at net asset value
— — — 226,526 
Venture capital and private equity fund investments not measured at net asset value (1)
— — 134 134 
Other equity securities in public companies26,205 203,092 — 229,297 
Total non-marketable and other equity securities (fair value accounting)
26,205 203,092 134 455,957 
Other assets:
Foreign exchange forward and option contracts— 145,591 — 145,591 
Equity warrant assets— 9,501 192,683 202,184 
Client interest rate derivatives— 79,270 — 79,270 
Total assets
$4,596,948 $21,771,035 $192,817 $26,787,326 
Liabilities:
Foreign exchange forward and option contracts$— $112,223 $— $112,223 
Client interest rate derivatives— 25,558 — 25,558 
Total liabilities
$— $137,781 $— $137,781 
(1)Included in Level 3 assets is $120 thousand attributable to noncontrolling interests calculated based on the ownership percentages of the noncontrolling interests.
The following fair value hierarchy table presents information about our assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2019:
(Dollars in thousands)Level 1Level 2Level 3Balance at December 31, 2019
Assets:
Available-for-sale securities:
U.S. Treasury securities$6,894,010 $— $— $6,894,010 
U.S. agency debentures— 99,547 — 99,547 
Foreign government debt securities9,038 — — 9,038 
Residential mortgage-backed securities:
Agency-issued mortgage-backed securities— 4,148,791 — 4,148,791 
Agency-issued collateralized mortgage obligations—fixed rate
— 1,538,343 — 1,538,343 
Agency-issued commercial mortgage-backed securities— 1,325,190 — 1,325,190 
Total available-for-sale securities6,903,048 7,111,871 — 14,014,919 
Non-marketable and other equity securities (fair value accounting):
Non-marketable securities:
Venture capital and private equity fund investments measured at net asset value— — — 265,263 
Venture capital and private equity fund investments not measured at net asset value (1)— — 134 134 
Other equity securities in public companies17,290 41,910 — 59,200 
Total non-marketable and other equity securities (fair value accounting)
17,290 41,910 134 324,597 
Other assets:
Foreign exchange forward and option contracts— 115,854 — 115,854 
Equity warrant assets— 4,435 161,038 165,473 
Interest rate swaps— 22,676 — 22,676 
Client interest rate derivatives— 28,811 — 28,811 
Total assets$6,920,338 $7,325,557 $161,172 $14,672,330 
Liabilities:
Foreign exchange forward and option contracts$— $98,207 $— $98,207 
Interest rate swaps— 25,623 — 25,623 
Client interest rate derivatives— 14,154 — 14,154 
Total liabilities$— $137,984 $— $137,984 
(1)Included in Level 3 assets is $120 thousand attributable to noncontrolling interests calculated based on the ownership percentages of the noncontrolling interests.
Additional Information about Level 3 Assets Measured at Fair Value on a Recurring Basis The following table presents additional information about Level 3 assets measured at fair value on a recurring basis for the three and nine months ended September 30, 2020 and 2019:
(Dollars in thousands)Beginning BalanceTotal Net Gains Included in
Net Income
PurchasesSales/ExitsIssuances  Distributions and Other SettlementsTransfers Out of Level 3Ending Balance
Three months ended September 30, 2020
Non-marketable and other equity securities (fair value accounting):
Venture capital and private equity fund investments not measured at net asset value (1)
$134 $— $— $— $— $— $— $134 
Other assets:
Equity warrant assets (2)165,225 52,537 — (28,760)4,605 — (924)192,683 
Total assets$165,359 $52,537 $— $(28,760)$4,605 $— $(924)$192,817 
Three months ended September 30, 2019
Non-marketable and other equity securities (fair value accounting):
Venture capital and private equity fund investments not measured at net asset value (1)
$441 $57 $— $(364)$— $— $— $134 
Other assets:
Equity warrant assets (2)147,770 39,527 — (45,270)4,130 — (1,116)145,041 
Total assets$148,211 $39,584 $— $(45,634)$4,130 $— $(1,116)$145,175 
Nine months ended September 30, 2020
Non-marketable and other equity securities (fair value accounting):
Venture capital and private equity fund investments not measured at net asset value (1)
$134 $$— $(5)$— $— $— $134 
Other assets:
Equity warrant assets (2)161,038 91,224 — (74,110)15,894 — (1,363)192,683 
Total assets$161,172 $91,229 $— $(74,115)$15,894 $— $(1,363)$192,817 
Nine months ended September 30, 2019
Non-marketable and other equity securities (fair value accounting):
Venture capital and private equity fund investments not measured at net asset value (1)
$1,079 $12 $— $(960)$— $$— $134 
Other assets:
Equity warrant assets (2)145,199 105,338 575 (113,143)11,714 — (4,642)145,041 
Total assets$146,278 $105,350 $575 $(114,103)$11,714 $$(4,642)$145,175 
 
(1)Realized and unrealized gains (losses) are recorded in the line item “Gains on investment securities, net," a component of noninterest income.
(2)Realized and unrealized gains (losses) are recorded in the line item “Gains on equity warrant assets, net," a component of noninterest income.
Unrealized Gains Included in Earnings Attributable to Level 3 Assets Held
The following table presents the amount of net unrealized gains and losses included in earnings (which is inclusive of noncontrolling interest) attributable to Level 3 assets still held at September 30, 2020 and 2019:
Three months ended September 30,Nine months ended September 30,
(Dollars in thousands)2020201920202019
Non-marketable and other equity securities (fair value accounting):
Venture capital and private equity fund investments not measured at net asset value (1)
$— $57 $— $12 
Other assets:
Equity warrant assets (2)26,360 (727)33,469 21,041 
Total unrealized gains (losses) , net$26,360 $(670)$33,469 $21,053 
Unrealized losses attributable to noncontrolling interests (1)$— $(158)$— $(199)
(1)Unrealized gains (losses) are recorded in the line item “Gains on investment securities, net," a component of noninterest income.
(2)Unrealized gains (losses) are recorded in the line item “Gains on equity warrant assets, net," a component of noninterest income.
Quantitative Information About Significant Unobservable Inputs
The following table presents quantitative information about the significant unobservable inputs used for certain of our Level 3 fair value measurements at September 30, 2020 and December 31, 2019. We have not included in this table our venture capital and private equity fund investments (fair value accounting) as we use net asset value per share (as obtained from the general partners of the investments) as a practical expedient to determine fair value.
(Dollars in thousands)Fair valueValuation TechniqueSignificant Unobservable InputsInput RangeWeighted 
Average
September 30, 2020:
Venture capital and private equity fund investments (fair value accounting)
$134 Private company equity pricing(1)(1)(1)
Equity warrant assets (public portfolio)1,166 Black-Scholes option pricing modelVolatility
45.1% - 56.8%
51.9 %
Risk-Free interest rate
0.3- 0.7
0.6 
Sales restrictions discount (2)
10.0 - 20.0
15.9 
Equity warrant assets (private portfolio)191,517 Black-Scholes option pricing modelVolatility
23.9 - 56.8
43.6 
Risk-Free interest rate
0.01 - 0.69
0.2 
Marketability discount (3)22.122.1 
Remaining life assumption (4)45.045.0 
December 31, 2019:
Venture capital and private equity fund investments (fair value accounting)
$134 Private company equity pricing(1)(1)(1)
Equity warrant assets (public portfolio)346 Black-Scholes option pricing modelVolatility
39.2% - 54.8%
50.7 %
Risk-Free interest rate1.91.9 
Sales restrictions discount (2)
10.0 - 20.0
13.6 
Equity warrant assets (private portfolio)160,692 Black-Scholes option pricing modelVolatility
23.6 - 54.8
38.2 
Risk-Free interest rate
0.5 - 1.9
1.6 
Marketability discount (3)17.517.5 
Remaining life assumption (4)45.045.0 
(1)In determining the fair value of our venture capital and private equity fund investment portfolio (not measured at net asset value), we evaluate a variety of factors related to each underlying private portfolio company including, but not limited to, actual and forecasted results, cash position, recent or planned transactions and market comparable
companies. Additionally, we have ongoing communication with the portfolio companies and venture capital fund managers, to determine whether there is a material change in fair value. We use company provided valuation reports, if available, to support our valuation assumptions. These factors are specific to each portfolio company and a weighted average or range of values of the unobservable inputs is not meaningful.
(2)We adjust quoted market prices of public companies, which are subject to certain sales restrictions. Sales restriction discounts generally range from 10 percent to 20 percent depending on the duration of the sales restrictions, which typically range from three to six months.
(3)Our marketability discount is applied to all private company warrants to account for a general lack of liquidity due to the private nature of the associated underlying company. The quantitative measure used is based upon various option-pricing models. On a quarterly basis, a sensitivity analysis is performed on our marketability discount.
(4)We adjust the contractual remaining term of private company warrants based on our estimate of the actual remaining life, which we determine by utilizing historical data on terminations and exercises. At September 30, 2020, the weighted average contractual remaining term was 6.2 years, compared to our estimated remaining life of 2.8 years. On a quarterly basis, a sensitivity analysis is performed on our remaining life assumption.
Summary of Estimated Fair Values of Financial Instruments Not Carried at Fair Value The following fair value hierarchy table presents the estimated fair values of our financial instruments that are not carried at fair value at September 30, 2020 and December 31, 2019:
  Estimated Fair Value
(Dollars in thousands)Carrying AmountTotalLevel 1Level 2Level 3
September 30, 2020:
Financial assets:
Cash and cash equivalents$15,687,776 $15,687,776 $15,687,776 $— $— 
Held-to-maturity securities
12,982,223 13,612,463 — 13,612,463 — 
Non-marketable securities not measured at net asset value
228,564 228,564 — — 228,564 
Non-marketable securities measured at net asset value
293,269 293,269 — — — 
Net commercial loans33,552,513 34,091,696 — — 34,091,696 
Net consumer loans4,348,420 4,418,614 — — 4,418,614 
FHLB and Federal Reserve Bank stock61,232 61,232 — — 61,232 
Financial liabilities:
Short-term borrowings19,068 19,068 — 19,068 — 
Non-maturity deposits (1)84,438,332 84,438,332 84,438,332 — — 
Time deposits334,687 273,785 — 273,785 — 
3.50% Senior Notes348,257 378,606 — 378,606 — 
3.125% Senior Notes495,173 557,495 — 557,495 — 
Off-balance sheet financial assets:
Commitments to extend credit— 34,126 — — 34,126 
December 31, 2019:
Financial assets:
Cash and cash equivalents$6,781,783 $6,781,783 $6,781,783 $— $— 
Held-to-maturity securities
13,842,946 14,115,272 — 14,115,272 — 
Non-marketable securities not measured at net asset value
195,405 195,405 — — 195,405 
Non-marketable securities measured at net asset value
235,351 235,351 — — — 
Net commercial loans29,104,532 29,615,176 — — 29,615,176 
Net consumer loans3,755,180 3,820,804 — — 3,820,804 
FHLB and Federal Reserve Bank stock60,258 60,258 — — 60,258 
Financial liabilities:
Short-term borrowings17,430 17,430 — 17,430 — 
Non-maturity deposits (1)61,569,714 61,569,714 61,569,714 — — 
Time deposits188,093 187,980 — 187,980 — 
3.50% Senior Notes347,987 366,856 — 366,856 — 
Off-balance sheet financial assets:
Commitments to extend credit— 27,197 — — 27,197 
(1)Includes noninterest-bearing demand deposits, interest-bearing checking accounts, money market accounts and interest-bearing sweep deposits.
Summary of Estimated Fair Values of Investments and Remaining Unfunded Commitments for Each Major Category of Investments
The following table is a summary of the estimated fair values of these investments and remaining unfunded commitments for each major category of these investments as of September 30, 2020:
(Dollars in thousands)Carrying Amount      Fair Value        Unfunded Commitments      
Non-marketable securities (fair value accounting):
Venture capital and private equity fund investments (1)$226,524 $226,524 $9,133 
Non-marketable securities (equity method accounting):
Venture capital and private equity fund investments (2)274,721 274,721 11,201 
Debt funds (2)6,918 6,918 240 
Other investments (2)11,629 11,629 886 
Total$519,792 $519,792 $21,460 
(1)Venture capital and private equity fund investments within non-marketable securities (fair value accounting) include investments made by our managed funds of funds and one of our direct venture funds (consolidated VIEs) and investments in venture capital and private equity fund investments (unconsolidated VIEs). Collectively, these investments in venture capital and private equity funds are primarily in U.S. and global technology and life science/healthcare companies. Included in the fair value and unfunded commitments of fund investments under fair value accounting are $55.0 million and $3.2 million, respectively, attributable to noncontrolling interests. It is estimated that we will receive distributions from the fund investments over the next 10 to 13 years, depending on the age of the funds and any potential extensions of terms of the funds.
(2)Venture capital and private equity fund investments, debt funds, and other fund investments within non-marketable securities (equity method accounting) include funds that invest in or lend money to primarily U.S. and global technology and life science/healthcare companies. It is estimated that we will receive distributions from the funds over the next 5 to 8 years, depending on the age of the funds and any potential extensions of the terms of the funds.